An interventional study of Coherent Breathing Group A and Regular Paced Breathing Group B in Pulmonary Disease, Chronic Obstructive (COPD), sponsored by Foundation University Islamabad. Recruiting at 1 site in Pakistan. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Foundation University Islamabad · Not applicable, Interventional, and Treatment
Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory condition of airways characterized by recurrent episodes of coughing, respiratory muscle weakness, lung hyperinflation and air trapping which ultimately leads to dyspnea, impaired pulmonary function and reduced quality of life.
Non- pharmacological approaches, particularly breathing retraining techniques, have gained recognition as complementary strategies for optimizing COPD management by improving overall functional status and exercise tolerance in the patients.
Chronic Obstructive Pulmonary Disease is a progressive lung condition which is characterized by persistent airflow limitation that gradually worsens over time.
The alveolar air sacs become damaged, and bronchial tubes narrow due to inflammation and increased mucus production. Theses structural and inflammatory changes significantly impair the airflow, reduce the efficiency of gas exchage and make the breathing dfficult.
Breathing exercises are an important component of non-pharmacological management in patients with COPD.
Among different breathing techniques, coherent breathing and regular paced breathing have been used to promote controlled respiratory patterns and improve breathing efficiency.
A total of 46 participants will be allocated into two groups. Group A will perform Coherent breathing and Group B will perform Regular Paced breathing along with pharmacological management.
The objective of this study is to compare the effects of Coherent Breathing versus Regular Paced Breathing on dyspnea, pulmonary function and quality of life in patients with COPD.
3,319 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's planned enrollment of 46 is below the median of 71 across 2,122 interventional studies indexed under Lung Diseases.
Browse Lung Diseases studies →Foundation University Islamabad is the lead sponsor of 253 studies on the registry; 140 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Mild: FEV1 ≥ 80% predicted Moderate: FEV1 fall between 50-79%
Exclusion Criteria:
Patients in this group will perform coherent breathing along with pharmacological management. Two sessions per week, supervised by physiotherapist will be conducted for a total of 4 weeks.
Other: Coherent Breathing Group A
Patients in this group will perform regular paced breathing along with pharmacological management. Two sessions per week, supervised by physiotherapist will be conducted for a total of 4 weeks.
Other: Regular Paced Breathing Group B
Participants in this group will perform coherent breathing exercises in addition to standard pharmacological management. The intervention will consist of two supervised sessions per week, conducted by a physiotherapist, for a total duration of 4 weeks. Exercises will be performed according to the participant's tolerance and clinical condition.
Regular paced breathing along with pharmacological management. Description: Patients in this group will perform regular paced breathing along with pharmacological management. A total 4 weeks protocol will be followed in which 2 sessions per week will be supervised by physiotherapist and 3 days at home. Regular Paced Breathing includes: The patient will be instructed to sit comfortably in an upright position with back supported and feet flat on floor. Patient will be guided to breathe at a normal, comfortable pace of 12-15 breaths/min. Inhale gently through nose for about 2 seconds. Exhale gently through mouth for about 2-3 seconds. Patients will be instructed not to hold their breath and do not take deep breaths. Participants will be instructed to maintain a record of their daily breathing practices. It will be performed for 8-10 minutes per session with rest breaks in between. Pharmacological management: Patient will receive medications as per prescribed by pulmonologist.
Dyspnea
Dyspnea will be assessed using the Modified Medical Research Council Dyspnea Scale (mMRC), which ranges from 0 to 4, where 0 indicates breathlessness only during strenuous exercise and 4 indicates severe breathlessness that limits activities such as leaving the house or dressing. Higher scores indicate greater severity of dyspnea and worse functional status.
Time frame: 4 weeks
Pulmonary Function
Pulmonary function will be assessed using spirometry by measuring forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), and the FEV₁/FVC ratio. Forced expiratory volume in one second and forced vital capacity will be recorded in liters and, where available, as percentages of predicted values. The FEV₁/FVC ratio will be expressed as a percentage. Lower values generally indicate poorer pulmonary function, although interpretation will be based on the individual spirometric parameters and appropriate reference values.
Time frame: 04 weeks
Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
Of 458 non-industry interventional studies with no phase under Lung Diseases, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 10 months is below that.
Counting every sponsor, half of 489 studies reached it within 21 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Foundation University Islamabad →